Enforcement Report - Week of January 25, 2023
Enforcement Report - Week of February 16, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic?focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and distributed through Harrow’s wholly owned subsidiary, ImprimisRx, combined with the Company’s existing ophthalmic?focused product portfolio, support Harrow’s growing ophthalmic surgical and acute care market presence.
Health Canada Issues Recalls Kit Care Corporation`s Safetec Triple Antibiotic Ointment
Enforcement Report - Week of August 7, 2019
Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products
Enforcement Report - Week of October 24, 2018
MicuRx Announces Funding from CARB-X for Innovative Polymyxin Antibiotic MRX-8
Aurobindo`s Generic Polymyxin B Sulfate approved in US for eye infections